Taipei, Taiwan

Been-Ren Lin

This inventor holds 1 USPTO granted patent and 3 published patent applications. Top assignee: Other. Active years: 2014.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Been-Ren Lin. Retrieved from https://idiyas.com/inventor/been-ren-lin

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 1 

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:

goldMedal1 out of 834,453 
Other
 patents

Years Active: 2014

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations by Been-Ren Lin

Introduction

Been-Ren Lin is a notable inventor based in Taipei, Taiwan. He has made significant contributions to the field of pharmaceuticals, particularly in cancer treatment. His innovative approach focuses on methods to inhibit peritoneal dissemination of cancer cells.

Latest Patents

Been-Ren Lin holds 1 patent for his work titled "Methods for inhibiting peritoneal dissemination of cancer cells." This patent describes a pharmaceutical composition that includes an effective dose of connective tissue growth factor (CTGF) along with a pharmaceutically acceptable carrier. This composition aims to treat or prevent the spread of cancer cells within the peritoneal cavity.

Career Highlights

Throughout his career, Been-Ren Lin has demonstrated a commitment to advancing medical science. His research has the potential to improve treatment options for patients suffering from cancer, showcasing his dedication to innovation in healthcare.

Collaborations

Been-Ren Lin has worked alongside talented colleagues, including Min-Liang Kuo and Cheng-Chi Chang. Their collaborative efforts contribute to the advancement of research in their respective fields.

Conclusion

Been-Ren Lin's innovative work in cancer treatment exemplifies the impact of dedicated inventors in the medical field. His contributions are paving the way for new therapeutic options that could benefit many patients in the future.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…